Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;54(1):713-722.
doi: 10.1080/07853890.2022.2046287.

Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma

Affiliations

Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma

Kim Oren Gradel et al. Ann Med. 2022 Dec.

Abstract

Objectives and study design: In this population-based study of 602 patients, we amended C-reactive protein (CRP) and plasma albumin (PA) levels around the diagnosis of diffuse large B-cell lymphoma (DLBCL) to the International Prognostic Index (IPI) and assessed 0-90, 91-365, and +365-day survival.Results: The CRP did not contribute to the IPI's prognostic or discriminatory ability, regardless of time period, particularly not in models with PA. In contrast, the PA was an important contributor, especially in the 0-90 day period, but also up to one year after the diagnosis. For day 0-90, the model with the IPI only had an Area Under the Receiver Operating Characteristics (AUROC) of 0.742, whereas the IPI with PA as a continuous variable rendered an AUROC of 0.841. Especially the lower PA quartile (18-32 g/L) contributed to the worse prognosis.Conclusions: The amendment of PA to the IPI may significantly improve the short-term prognostic and discriminative ability.Key messagesThe amendment of the plasma albumin (PA) level to the International Prognostic Index significantly improved the prediction of mortality up to one year after the diagnosis of diffuse large B-cell lymphoma.It was especially the lower quartile of the PA level (18-32 g/L) that contributed to the worse prognosis.

Keywords: C-reactive protein; Diffuse large B-cell lymphoma; inflammation; plasma albumin; prognosis.

PubMed Disclaimer

Conflict of interest statement

TSL: Bristol Myers Squibb/Celgene, Novartis, Roche, Gilead, Takeda – consultancy/advisory boards.

HF received support outside this work from Alexion, Gilead, Abbvie, Janssen Pharmaceuticals, and Novartis.

FGZ received grants for investigator initiated clinical trials from Bactiguard, Sweden, and Ionis Pharmaceuticals, USA.

RBD reports personal fees from Roche Diagnostics, outside the submitted work.

KOG, PJV, MI, PP, SLN, JKM, TGJ, MC, JEC, JJ report no conflict of interest.

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival curves, 0–365 days, for C-reactive protein quartiles, plasma albumin quartiles, and International Prognostic Index scores.
Figure 2.
Figure 2.
Mortality rate ratios of combinations of International Prognostic Index (IPI) scores (low, low/intermediate, high/intermediate, high), plasma albumin quartiles (red: lower quartile [18–32 g/L]; blue: 2nd quartile [33–37 g/L]; green: 3rd quartile [38–41 g/L]; black: upper quartile [42–52 g/L]), and C-reactive protein quartiles (X: lower quartile [0–4.8 mg/L]; hollow triangle: 2nd quartile [5–24 mg/L]; hollow diamond: 3rd quartile [25–79 mg/L]; hollow circle: upper quartile [80–433 mg/L]).

Similar articles

Cited by

References

    1. Morton LM, Wang SS, Devesa SS, et al. . Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265–276. Jan 1 - PMC - PubMed
    1. Jelicic J, Larsen TS, Frederiksen H, et al. . Statistical challenges in development of prognostic models in diffuse large B-cell lymphoma: comparison between existing models - A Systematic Review. Clin Epidemiol. 2020;12:537–555. - PMC - PubMed
    1. Oken MM, Creech RH, Tormey DC, et al. . Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982; 5(6):649–655. - PubMed
    1. International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. NEJM. 1993; 329(14):987–994. - PubMed
    1. Zhou Z, Sehn LH, Rademaker AW, et al. . An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842. - PMC - PubMed

Publication types